New pharmacological directions for the treatment of overweight and obesity.
Van Gaal
L F
LF
Dept. of Endocrinology, Metabolism and Clinical Nutrition, University Hospital Antwerp, Belgium. luc.van.gaal@uza.uia.ac.be
Peiffer
F W
FW
De Leeuw
I H
IH
D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D001067:Appetite Depressants / Q000627:therapeutic use; D015992:Body Mass Index; D001835:Body Weight; D003503:Cyclobutanes / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D007783:Lactones / Q000627:therapeutic use; D009765:Obesity / Q000188:drug therapy* / Q000601:surgery; D009767:Obesity, Morbid / Q000188:drug therapy / Q000601:surgery; D000077403:Orlistat; D018579:Patient Selection; D015431:Weight Loss
D019440:Anti-Obesity Agents; D001067:Appetite Depressants; D003503:Cyclobutanes; D004791:Enzyme Inhibitors; D007783:Lactones; D000077403:Orlistat; C058254:sibutramine